LUMO News and Press, Lumos Pharma Inc. From 01/05/22

AUSTIN, Texas, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will present at the H.C. Wainwright Virtual BIOCONNECT Conference being held January 10-13,...

Gainers: Galera Therapeutics (NASDAQ:GRTX) +11%. TFF Pharmaceuticals TFFP +7%. Annexon (NASDAQ:ANNX) +6%. Clarus Therapeutics Holdings (NASDAQ:CRXT) +4%. Tyra Biosciences (NASDAQ:TYRA) +4%. Losers: CalAmp CAMP -14%. Qilian International Holding Group  (NASDAQ:QLI) -4%...

Lumos Pharma, Inc. (LUMO) Q3 2021 Earnings Conference Call November 3, 2021 16:30 ET Company Participants Lisa Miller - Senior Director of Investor Relations Rick Hawkins - Chief Executive Officer & Chairman Lori Lawley - Chief Financial Officer & Principal Accounting Officer Conferen...

Majority of OraGrowtH210 Trial sites are open with recent and imminent openings representing historically high enrollment sites Six-month primary outcome data readout from OraGrowtH210 expected 2H 2023 AUSTIN, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma...

AUSTIN, Texas, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its third quarter 2021 financial results after market close on Wednesday, November 3, 2...

AUSTIN, Texas, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 23 rd Annual Global Investment Conference and ...

The following slide deck was published by Lumos Pharma, Inc. in conjunction with this event. For further details see: Lumos Pharma Corporate Presentation

Lumos Pharma, Inc. (LUMO) Q2 2021 Earnings Conference Call August 05, 2021, 11:00 AM ET Company Participants Lisa Miller - Senior Director-IR Rick Hawkins - CEO and Chairman John McKew - President and Chief Scientific Officer David Karpf - Chief Medical Officer Lori Lawley - CFO and Corporate...

Lumos Pharma (NASDAQ:LUMO): Q2 GAAP EPS of -$1.04 misses by $0.01. Revenue of $0.01M (-66.7% Y/Y) Press Release For further details see: Lumos Pharma EPS misses by $0.01

• Lumos Pharma strengthens leadership team with promotion of John McKew, PhD to President, and addition of David B. Karpf, MD as Chief Medical Officer and Mark Bach, MD, PhD to Advisory Board • Screening and enrollment of OraGrowtH210 and OraGrowtH212 Trials progre...